RESMED INC (RMD) Form 10-Q — Oct 29, 2026
ResMed's Q1 fiscal 2027 10-Q showed net revenue of $1.415 billion, up 6% year over year (7% core constant currency), with Sleep and Breathing Health revenue up 8% to $1.26 billion. Net income rose 20% to $418 million and diluted EPS rose 23% to $2.92, boosted by a $62 million pre-tax gain on the September 1, 2026 sale of the MatrixCare business for $470 million in net cash proceeds. Gross margin expanded to 61.5% from 61.2%. The company deployed capital aggressively, repurchasing 3.6 million shares for $855 million including a $450 million accelerated share repurchase, paying $95 million in dividends ($0.66 per share), and repaying $250 million of senior notes.
Key figures
- Eps
- 2.92
- Revenue
- 1414814000
- Net Income
- 418413000
- Total Debt
- 410000000
- Revenue Yoy
- 6%
- Total Assets
- 8211811000
- Cash Position
- 1010742000
- Shares Outstanding
- 140657071
- Asr amount
- 450000000
- Gross margin
- 61.5%
- Dividends paid
- 94954000
- Available revolver
- 1500000000
- Effective tax rate
- 22.4%
- Gain on divestiture
- 61784000
- Operating cash flow
- 422422000
- Net income prior year
- 348536000
- Senior notes 3 45 due
- July 10, 2029
- Diluted eps prior year
- 2.37
- Gross margin prior year
- 61.2%
- Q1 share repurchases cost
- 855000000
- Q1 share repurchases shares
- 3600000
- Asr initial shares delivered
- 1600000
- Quarterly dividend per share
- 0.66
- Sleep breathing health growth
- 8%
- Shares remaining under buyback
- 4300000
- Sleep breathing health revenue
- 1259802000
- Matrixcare divestiture proceeds
- 470000000
- Residential care software change
- (7)%
- Remaining performance obligations
- 386000000
- Residential care software revenue
- 155012000
- Core constant currency revenue growth
- 7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.